GNH USA

Europe — EMA

Mresvia

GNH USA supplies Mresvia (RSV mRNA vaccine), a prophylactic vaccine for prevention of respiratory syncytial virus infection. Request a quote for supply.

Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In

Request sourcing

1
Pack/s

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Single‑Stranded 5' Capped mRNA Encoding the RSV F Glycoprotein, the active ingredient in Mresvia, is a vaccine presented as an intramuscular injection for prophylactic use. It is intended to prevent respiratory syncytial virus infection in infants, older adults, immunocompromised individuals, and other at‑risk groups, offering seasonal protection against RSV disease.

GNH USA supplies Mresvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution networks across the EU and other global markets, and adhering to stringent quality standards.

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In used for?

Mresvia is an mRNA vaccine that targets the respiratory syncytial virus (RSV) to prevent infection. - Prevention of RSV infection: Provides immunity against respiratory syncytial virus in infants, older adults, and other at‑risk populations. - Seasonal prophylaxis: Reduces incidence of RSV‑related lower respiratory tract disease during the RSV season. - Hospitalized patients at risk: Helps lower RSV‑related complications in high‑risk hospitalized individuals.

What are the side effects of Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Mresvia, like other vaccines, may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: Mild to moderate discomfort at the injection site. - Redness or swelling: Localized erythema or edema that resolves within a few days. - Fever: Transient low‑grade fever occurring within 24‑48 hours. - Headache or fatigue: Generalised tiredness or mild headache post‑vaccination.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: Rare neurological disorder presenting with muscle weakness. - Myocarditis or pericarditis: Inflammation of heart muscle or surrounding tissue. - Thrombocytopenia: Low platelet count that may cause abnormal bleeding. - Seizures: Uncommon neurologic event, especially in febrile infants.

What precautions apply to Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Before administering Mresvia, certain precautions should be observed. - Screen for severe allergic reactions: Avoid administration in individuals with known hypersensitivity to any vaccine component. - Observe after injection: Monitor for at least 15 minutes for immediate reactions. - Pregnancy considerations: Use only if the expected benefit outweighs potential risk; consult a healthcare provider. - Immunocompromised patients: May have reduced response; evaluate risk‑benefit carefully. - Concurrent vaccines: May be given with other vaccines at different anatomical sites. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In interact with?

Mresvia may interact with certain medical products or conditions.

Major Interactions (Avoid): - Live attenuated vaccines: Concomitant use may interfere with immune response; avoid simultaneous administration. - Immunosuppressive therapy: May diminish vaccine efficacy; avoid if possible during active immunosuppression. - Severe allergic reaction to a previous dose: Contraindicated.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): May mask fever; use as needed. - Other injectable vaccines: May increase local reactogenicity; separate injection sites. - Blood products within 4 weeks: Could affect immune response; monitor patient closely.

Frequently asked questions

What is Mresvia used for?+
Mresvia is a prophylactic mRNA vaccine designed to prevent infection with respiratory syncytial virus (RSV). It is indicated for individuals at increased risk of severe RSV disease, including infants, young children, older adults, and immunocompromised patients.
How does the RSV mRNA vaccine work?+
The vaccine contains messenger RNA that encodes the RSV F glycoprotein. After intramuscular injection, host cells translate the mRNA into the F protein, which is then displayed to the immune system. This triggers both antibody‑mediated and cellular immune responses, creating protective immunity against future RSV exposure.
What is the usual dose of Mresvia?+
The dosing regimen for Mresvia is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. No specific dose information is provided here; clinicians should refer to the product label and relevant regulatory guidance.
Is Mresvia safe during pregnancy or breastfeeding?+
Safety data for Mresvia in pregnancy and lactation are limited. It should only be administered to pregnant or breastfeeding individuals when the potential benefit justifies any possible risk. Healthcare providers should discuss individual circumstances and current recommendations before vaccination.
How do I order Mresvia from GNH USA?+
To order Mresvia, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.
How does Mresvia compare with other RSV vaccines?+
Mresvia uses a single‑stranded mRNA platform to express the RSV F protein, whereas some alternative RSV vaccines rely on recombinant protein or live‑attenuated virus technologies. The mRNA approach can induce both humoral and cellular immunity and may be produced more rapidly, but comparative efficacy and safety depend on clinical trial data and population specifics.
What are the storage and handling requirements for Mresvia?+
Mresvia must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.
How is Mresvia administered?+
Mresvia is given as a single intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique. The site should be observed for any immediate adverse reactions following administration.
What are the most serious risks to watch for with Mresvia?+
The most serious adverse events reported with Mresvia include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, myocarditis or pericarditis, and rare cases of thrombocytopenia. Patients should be monitored after vaccination and instructed to seek immediate medical care if they experience symptoms like difficulty breathing, swelling of the face or throat, or unexplained weakness.
Who should not receive Mresvia?+
Mresvia should not be administered to individuals with a known severe allergy to any component of the vaccine or to those who have experienced a serious adverse reaction (e.g., anaphylaxis) after a previous dose. It is also contraindicated in persons with active, uncontrolled immunosuppression where vaccine efficacy cannot be assured.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In
Route
Intramuscular Use
Manufacturer
Moderna Biotech Spain S. L.
Origin
EU